/MDGL
Madrigal Pharmaceuticals, Inc.
MDGL • NASDAQMDGL • NASDAQ • Healthcare
$443.67+1.13%+4.94
$443.67+1.13%(+4.94)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
100Low Risk
Momentum
41Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
94.1%▼2.4pp
Revenue after COGS
Operating
-31.3%▲245.1pp
After operating expenses
Net
-30.1%▲228.6pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-45.3
Price vs earnings
EV/EBITDA
-50.0
Enterprise value
FCF Yield
-1.5%
Cash generation
Earnings Yield
-2.2%
Inverse of P/E
Capital Efficiency
-35
GoAI Quality ScorePoor
ROEReturn on Equity
-47.8%Weak
ROAReturn on Assets
-22.9%Weak
ROICReturn on Invested Capital
-31.6%Weak
Financial Health
Current RatioHealthy
4.01
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.59x
Debt repayment capacity (<3x)
Income QualityFair
0.66
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $958.40M | $180.13M | N/A | N/A | N/A |
| Gross Profit | $902.25M | $173.90M | N/A | N/A | N/A |
| Gross Margin | 94.1% | 96.5% | N/A | N/A | N/A |
| Operating Income | -$300.10M | -$497.88M | -$380.50M | -$293.57M | -$242.48M |
| Net Income | -$288.28M | -$465.89M | -$373.63M | -$295.35M | -$241.85M |
| Net Margin | -30.1% | -258.6% | N/A | N/A | N/A |
| EPS | -$12.85 | -$21.90 | -$19.99 | -$17.23 | -$14.63 |
Average Price Target
$705.67▲ 59.1% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals, Inc., the average price target is $705.67, with a high forecast of $964.00 and a low forecast of $527.00. The average price target represents a 59.1% increase from the current price of $443.67.
Highest
$964.00
Average
$705.67
Lowest
$527.00
Rating Distribution
Strong Buy
0
0%
Buy
20
87%
Hold
2
9%
Sell
1
4%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
B of A Securities● Maintain
Neutral
2026-02-20Citizens● Maintain
Market Outperform
2026-01-20Piper Sandler● Maintain
Overweight
2025-12-19B. Riley Securities● Maintain
Buy
2025-12-11HC Wainwright & Co.● Maintain
Buy
2025-11-21Oppenheimer● Maintain
Outperform
2025-11-20Truist Securities● Maintain
Buy
2025-11-19Canaccord Genuity● Maintain
Buy
2025-11-13HC Wainwright & Co.● Maintain
Buy
2025-11-11Citizens● Maintain
Market Outperform
2025-11-05Earnings History & Surprises
BEAT RATE
50%
Last 18 quarters
AVG SURPRISE
-14.7%
EPS vs Estimate
BEATS / MISSES
9/9
Last 18 quarters
LATEST EPS
$-2.57
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-187.1%
$-2.57 vs $-0.90
Q4 '25
-149.4%
$-5.08 vs $-2.04
Q3 '25
+45.4%
$-1.90 vs $-3.48
Q2 '25
+8.3%
$-3.32 vs $-3.62
Q1 '25
+37.3%
$-2.71 vs $-4.32
Q4 '24
+29.1%
$-4.92 vs $-6.94
Q3 '24
+6.0%
$-7.10 vs $-7.55
Q2 '24
-21.8%
$-7.38 vs $-6.06
Q1 '24
-6.8%
$-5.68 vs $-5.32
Q4 '23
-11.7%
$-5.34 vs $-4.78
Q3 '23
-4.9%
$-4.69 vs $-4.47
Q2 '23
+15.1%
$-4.23 vs $-4.98
No investor questions available.
Latest News
No news available